**Jeffrey Sonnenfeld and Meg Tirrell argue the FDA needs AI to rebuild trust.**
The FDA has faced intense scrutiny over its handling of recent high-profile approvals, with many questioning the decision-making process behind these choices.
Avoiding a Perfect Storm
The agency’s struggles come at a time when the world is grappling with an unprecedented health crisis, and the public’s trust in the FDA is at an all-time low. The intersection of science, medicine, public health, and innovation is more complex than ever, making the agency’s task even more daunting.
However, the solution to the FDA’s woes might not lie in changing its processes or adding more regulators, but in adopting artificial intelligence (AI) to inform its decisions.
The Potential of AI in the FDA
By harnessing the power of AI, the FDA can sift through vast amounts of data, identify potential risks and benefits, and make more informed decisions. AI can also help the agency monitor the performance of approved products, identifying any potential safety concerns earlier and more effectively.
The use of AI in the FDA can help alleviate concerns around bias, as AI systems can be designed to eliminate bias and ensure transparency throughout the decision-making process.
A Prescription for Rebuilding Trust
What this means is that the FDA needs to prioritize the development and implementation of AI-powered decision-support tools. By doing so, the agency can demonstrate its commitment to transparency, accountability, and safety.
This shift will require significant investment, but the long-term benefits could be substantial. As Jeffrey A. Sonnenfeld, Senior Associate Dean for Leadership Studies & Lester Crown Professor in the Practice of Management, notes, “The FDA needs to be at the forefront of technology to maintain its credibility and trust.”
By embracing AI, the FDA can not only rebuild trust but also position itself as a leader in the use of advanced technologies to drive better health outcomes.
